Literature DB >> 33505941

Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea.

Sunmin Park1, Chai Hong Rim1, Young Kul Jung2, Won Sup Yoon1.   

Abstract

Background: We sought to analyze the preferred treatment modality by age and liver function in South Korea.
Methods: The Korean Liver Cancer Study Group randomly extracted the data of patients with hepatocellular carcinoma (HCC) enrolled in the Korean Central Cancer Registry from 2008 to 2014 from approximately 50 hospitals nationwide. After excluding distant and lymphatic metastases, the treatment preference for patients with a single lesion (excluding PVT (portal vein thrombosis), hepatic vessels, and bile duct invasion) and with PVT was evaluated in 7559 patients. Patients were grouped by age, and baseline liver function was divided based on the Child-Pugh class (CPC) A, B, and C.
Results: For a single HCC, the majority of patients selected transarterial therapy as the initial treatment, followed by surgical resection and local ablative therapy. The surgical resection rate decreased significantly with age (p < 0.001), and the transarterial therapy rate significantly increased (p < 0.001). For CPC C, liver transplantation was significantly increased to 11.5%, and 36.3% of patients received no treatment. In HCC with PVT, the transarterial therapy rate was the highest, followed by the rate of abandonment of treatment. The proportion of no treatment significantly increased with age (p < 0.001). In CPC C, transarterial therapy and systemic therapy were attempted in 15.4% and 5.8% of patients, respectively. Conclusions: Age and liver function have a significant impact on the therapeutic decision-making of HCC patients in Korea. In unfavorable conditions, surgical resection was less favored in patients with single tumors, and no treatment was preferred in patients with PVT.
Copyright © 2021 Sunmin Park et al.

Entities:  

Year:  2021        PMID: 33505941      PMCID: PMC7811492          DOI: 10.1155/2021/6640121

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  34 in total

Review 1.  Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis.

Authors:  Alessandro Granito; Luigi Bolondi
Journal:  Lancet Oncol       Date:  2017-02       Impact factor: 41.316

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 3.  A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes.

Authors:  Eunae Cho; Hyun A Cho; Chung Hwan Jun; Hee Joon Kim; Sung Bum Cho; Sung Kyu Choi
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

4.  Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.

Authors:  Mairéad Geraldine McNamara; Astrid E Slagter; Christina Nuttall; Melissa Frizziero; Rille Pihlak; Angela Lamarca; Noor Tariq; Juan W Valle; Richard A Hubner; Jennifer J Knox; Eitan Amir
Journal:  Eur J Cancer       Date:  2018-10-29       Impact factor: 9.162

5.  Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.

Authors:  Myeong Jun Song; Si Hyun Bae; June Sung Lee; Sung Won Lee; Do Seon Song; Chan Ran You; Jong Young Choi; Seung Kew Yoon
Journal:  Korean J Intern Med       Date:  2016-02-15       Impact factor: 2.884

6.  Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.

Authors:  Joong-Won Park; Minshan Chen; Massimo Colombo; Lewis R Roberts; Myron Schwartz; Pei-Jer Chen; Masatoshi Kudo; Philip Johnson; Samuel Wagner; Lucinda S Orsini; Morris Sherman
Journal:  Liver Int       Date:  2015-03-25       Impact factor: 5.828

7.  Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.

Authors:  Sheng-Long Ye; Jiamei Yang; Ping Bie; Shuijun Zhang; Xiaoping Chen; Fengyong Liu; Luming Liu; Jie Zhou; Kefeng Dou; Chunyi Hao; Guoliang Shao; Qiang Xia; Yajin Chen; Jijin Yang; Xiaxing Deng; Yunpeng Liu; Yunfei Yuan; Zhiren Fu; Keiko Nakajima; Zhengguang Lv
Journal:  BMC Cancer       Date:  2018-03-02       Impact factor: 4.430

8.  Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05).

Authors:  Sun Hyun Bae; Hee Chul Park; Won Sup Yoon; Sang Min Yoon; In-Hye Jung; Ik Jae Lee; Jun Won Kim; Jinsil Seong; Tae Hyun Kim; Taek-Keun Nam; Youngmin Choi; Sun Young Lee; Hong Seok Jang; Dong Soo Lee; Jin Hee Kim
Journal:  Cancer Res Treat       Date:  2019-04-10       Impact factor: 4.679

9.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016.

Authors:  Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Eun Sook Lee
Journal:  Cancer Res Treat       Date:  2019-03-18       Impact factor: 4.679

10.  Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival.

Authors:  Kichang Han; Jin Hyoung Kim; Hee Mang Yoon; Eun-Joung Kim; Dong Il Gwon; Gi-Young Ko; Hyun-Ki Yoon; Heung Kyu Ko
Journal:  Korean J Radiol       Date:  2014-07-09       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.